New Orleans
,
US
7 - 10 November 2025
American Heart Association (AHA 2025)
Presentation schedule and materials
Saturday, 08 November 2025
11:15
- 12:00
CT
Symposium
The heart of the matter: Cardiovascular outcomes with GLP-1RAs
Michael Lincoff
;
Erin Bohula
;
Marc P. Bonaca
MATERIALS AVAILABLE
12:50
- 12:55
CT
MP488
POSTER
Semaglutide 2.4 mg Real-world Risk Reduction of Cardiometabolic Comorbidities and Improvement in Biomarkers among Patients with Overweight or Obesity (SMILE)
Aleksandrina Ruseva1; Matthew Bassan1; Ella Xiaoyan Du2; Anthony Fabricatore1; Briain O Hartaigh1; Wojciech Michalak1; Ramya Ramasubramanian2; Pangsibo Shen2; Jinlin Song2; Zhenxiang Zhao1; Francisco Lopez-Jimenez3
MATERIALS AVAILABLE
14:30
- 15:30
CT
Sa2021
POSTER
Systemic Inflammation Is Associated with Major Adverse Cardiovascular Events in Patients with Established Atherosclerotic Cardiovascular Disease and Stage 3-4 Chronic Kidney Disease
Chi Nguyen, PhD1; Radha Ryali, MS1; Jeffrey R Skaar, PhD1; Wing Chow, PharmD, MPH1; Carey Robar, MD1; Allegra Kaufman, MD1; Weilong Li, PhD1; Binita Shah, MD2
MATERIALS AVAILABLE
14:30
- 15:30
CT
Sa3069
POSTER
Efficacy and safety of semaglutide according to frailty status in the SELECT trial
John W. Ostrominski1,2; Jorge Plutzky1; Benjamin M. Scirica1; G. Kees Hovingh3,4; Ole Kleist Jeppesen3 A. Michael Lincoff5; Ildiko Lingvay6; Thomas Hoffmann Morville3; María De Los Angeles Quiroga Peláez3; Yael Sofer7,8; Miguel Urina-Triana9; Vanita R. Aroda9
MATERIALS AVAILABLE
15:43
- 15:48
CT
MP458
POSTER
Clinical Outcomes Among Individuals with Persistent Systemic Inflammation Following Myocardial Infarction: Insights from the Veterans Affairs Healthcare System
Alexander T Sandhu, MD MS1; Adam Furst, MS1; Fatima Rodriguez, MD1; Neil Kalwani, MD1; Shriram Nallamshetty, MD1; Natasha Din, MBBS MAS1; Michael Fan, PharmD2; Kat Khachatourian, PharmD2; Jeffrey R. Skaar, PhD2; Ivy Tonnu-Mihara, PharmD, MS2
MATERIALS AVAILABLE
15:57
- 16:02
CT
MP460
POSTER
Temporal Trends in Outcomes Following Hospitalization for Myocardial Infarction Between 2008-2022: Insights from the Veterans Affairs Healthcare System
Alexander T Sandhu, MD MS1; Adam Furst, MS1; Fatima Rodriguez, MD, MPH1; Neil Kalwani, MD1; David Maron, MD1; Shriram Nallamshetty, MD1; Natasha Din, MBBS MAS1; Michael Fan, PharmD2; Kat Khachatourian, PharmD2; Jeffrey R. Skaar, PhD2; Ivy Tonnu-Mihara, PharmD MS2
MATERIALS AVAILABLE
Monday, 10 November 2025
09:43
- 09:48
CT
MP2494
POSTER
Lower Risk of Cardiovascular Events in Patients with Heart Failure Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-HF Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Heart Failure Population)
Kim G. Smolderen1,2; Carlos-Mena Hurtado1; Victoria Divino3; Zhenxiang Zhao3; Yan Chen4; Joanna Boland4; Jinlin Song4; Briain O Hartaigh3; Prashanth Iyer3; Filip K. Knop5; Michael G. Nanna1
MATERIALS AVAILABLE
10:30
- 11:30
CT
Mo2046
POSTER
Performance of the Diabetes Outcomes Model in the United States (DOMUS) in a Large, Contemporary US Claims Dataset
Aaron Winn1; Uwes Siebert3; Gang Fang2; Lin Xie2; Caroline Swift2; Josh Noone2; Mico Guevarra2; Sherif Mehanna2; Neda Laiteerapong4
MATERIALS AVAILABLE
11:06
- 23:11
CT
MP2214
POSTER
Comparing cardiovascular outcomes in new users of oral semaglutide versus other noninsulin glucose-lowering therapies
Xi Tan1; Yuanjie Liang1; Caichen Zhong1; Lin Xie1; Mico Guevarra1; Caroline Swift1; Adam de Havenon2
MATERIALS AVAILABLE
11:20
- 11:25
CT
MP2216
POSTER
SELECT-LIFE: A non-interventional follow-up study investigating the long-term effects of semaglutide in participants from the SELECT trial
Ildiko Lingvay1; John E. Deanfield2; María De Los Angeles Quiroga Peláez3; Steven E. Kahn4; A. Michael Lincoff5; Jorge Plutzky6; Stine D. Ross3; Peter E. Weeke3; Donna H. Ryan7
MATERIALS AVAILABLE
11:41
- 11:46
CT
MP2219
POSTER
Lower Risk of Cardiovascular Events in Patients with Clinical Atherosclerotic Cardiovascular Disease Initiated on Semaglutide 2.4 mg in the Real-world: Results from the SCORE-Clinical ASCVD Study (Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity in the Real World – Clinical Atherosclerotic Cardiovascular Disease Population)
Kim G. Smolderen1,2; Carlos-Mena Hurtado1; Victoria Divino3; Zhenxiang Zhao3; Yan Chen4; Joanna Boland4; Jinlin Song4; Briain O Hartaigh3; Andrea Traina3; Kerem Ozer3; Filip K. Knop5; Michael G. Nanna1
MATERIALS AVAILABLE
14:00
- 14:12
CT
FS.10
ORAL PRESENTATION
Primary results from the phase 2 randomized, placebo controlled, blinded trial of the monoclonal antibody coramitug in transthyretin amyloid cardiomyopathy (ATTR-CM)
Marianna Fontana1; Pablo Garcia-Pavia2; Martha Grogan3; Sanjiv J Shah4; Mads D M Engelmann5; G Kees Hovingh5; Arnt V Kristen6; Michelle Lim-Watson7; Brian Malling7; Soumitra Kar8; Manjunatha Revanna5; Nitasha Sarswat9; Kenichi Tsujita10 Mathew S Maurer11
MATERIALS AVAILABLE
Keywords